Comparing the Antibody Response to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab or Natalizumab

Conditions:   Multiple Sclerosis;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases of the Nervous System;   Nervous System Diseases;   Demyelinating Diseases;   Autoimmune Diseases;   Immune System Diseases;   Pathologic Processes Intervention:   Device: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test Sponsor:   Dragonfly Research, LLC Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials